{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Primary+tumor+resection", "query": { "intervention": "Primary tumor resection" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 224, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Primary+tumor+resection&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T07:40:04.485Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03540017", "title": "HIPEC After Initial CRS in Patients Who Have Received NACT", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "FEMALE", "summary": "18 Years to 85 Years · Female only" }, "enrollment_count": 15, "start_date": "2019-03-12", "completion_date": "2025-07-05", "has_results": false, "last_update_posted_date": "2022-11-02", "last_synced_at": "2026-09-14T07:40:04.485Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03540017" }, { "nct_id": "NCT05535166", "title": "Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Medulloblastoma" ], "interventions": [ { "name": "Surgical resection", "type": "PROCEDURE" }, { "name": "Ommaya/VPS", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Irradiation", "type": "RADIATION" }, { "name": "Educational and Media Intervention", "type": "OTHER" }, { "name": "SOC, Educational and Media Intervention", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "OTHER" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "59 Months", "sex": "ALL", "summary": "Up to 59 Months" }, "enrollment_count": 130, "start_date": "2022-12-20", "completion_date": "2035-07", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-09-14T07:40:04.485Z", "location_count": 10, "location_summary": "Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05535166" }, { "nct_id": "NCT02323854", "title": "The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Ablation", "type": "DEVICE" }, { "name": "Surgical Resection", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Medtronic - MITG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2015-01", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2018-05-07", "last_synced_at": "2026-09-14T07:40:04.485Z", "location_count": 3, "location_summary": "Rochester, Minnesota • New York, New York • Providence, Rhode Island", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT02323854" }, { "nct_id": "NCT04317534", "title": "Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC, Stage I" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Greg Durm, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2020-05-05", "completion_date": "2028-04-08", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-09-14T07:40:04.485Z", "location_count": 13, "location_summary": "Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 10 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04317534" }, { "nct_id": "NCT04415944", "title": "Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Epithelial Cancer Stage I", "Ovarian Epithelial Cancer Stage II", "Ovarian Epithelial Cancer Stage III", "Stage I Fallopian Tube Cancer", "Stage II Fallopian Tube Cancer", "Stage III Fallopian Tube Cancer", "Peritoneal Carcinoma" ], "interventions": [ { "name": "Second look laparoscopy reassessment surgery (SLLRS)", "type": "PROCEDURE" }, { "name": "HIPEC with Carboplatin", "type": "DRUG" }, { "name": "FACT-O Quality of Life Questionnaire", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2021-05-20", "completion_date": "2026-01-23", "has_results": true, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-14T07:40:04.485Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04415944" }, { "nct_id": "NCT01280344", "title": "Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Dysmotility" ], "interventions": [ { "name": "Saline Solution for Injection", "type": "DRUG" }, { "name": "Ipamorelin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Therapeutics (U.S.), Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 320, "start_date": "2011-04", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2017-04-13", "last_synced_at": "2026-09-14T07:40:04.485Z", "location_count": 45, "location_summary": "Florence, Alabama • Sheffield, Alabama • Fountain Valley, California + 42 more", "locations": [ { "city": "Florence", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Laguna Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01280344" }, { "nct_id": "NCT01504126", "title": "Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage II Fallopian Tube Cancer AJCC v6 and v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage III Fallopian Tube Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Primary Peritoneal Cancer AJCC v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Propranolol Hydrochloride", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2012-03-09", "completion_date": "2019-08-15", "has_results": false, "last_update_posted_date": "2019-08-29", "last_synced_at": "2026-09-14T07:40:04.485Z", "location_count": 7, "location_summary": "Gilbert, Arizona • Houston, Texas • Sugar Land, Texas + 1 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01504126" }, { "nct_id": "NCT00049556", "title": "Gefitinib in Treating Patients With Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "surface-enhanced laser desorption/ionization-time of flight mass spectrometry", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "sentinel lymph node biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2002-10", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-09-14T07:40:04.485Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049556" }, { "nct_id": "NCT07044557", "title": "MeDex: No Perioperative Dexamethasone in Brain Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain Metastases" ], "interventions": [ { "name": "Withholding perioperative Dexamethasone", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2026-08-01", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-09-14T07:40:04.485Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT07044557" }, { "nct_id": "NCT01967537", "title": "Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Von Hippel-Lindau Syndrome", "Hippel-Lindau Disease" ], "interventions": [ { "name": "68Gallium DOTATATE", "type": "DRUG" }, { "name": "Radio-guided surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "10 Years to 99 Years" }, "enrollment_count": 341, "start_date": "2013-10-18", "completion_date": "2018-03-12", "has_results": true, "last_update_posted_date": "2019-11-19", "last_synced_at": "2026-09-14T07:40:04.485Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01967537" } ] }